Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Aprea Therapeutics, Inc. filed a Form 8-K reporting a Nasdaq continued-listing deficiency received on June 29, 2022. The report was signed on July 1, 2022. The company’s common stock trades under the symbol APRE on the Nasdaq Global Select Market.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating and financial metrics.
Material Change Versus the Prior Comparable Period
For the preceding 30 consecutive business days, Aprea’s common stock closing bid price was below Nasdaq’s $1.00-per-share minimum continued-listing requirement under Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Unusual Items
- The deficiency notice had no immediate effect on the company’s Nasdaq listing, and APRE continued to trade on Nasdaq as of the filing.
- Aprea was granted an initial 180-calendar-day compliance period ending December 26, 2022.
- To regain compliance during that period, the stock’s closing bid price must be at least $1.00 for a minimum of 10 consecutive business days.
- If the company does not regain compliance, it may qualify for an additional 180-calendar-day period if it transfers to the Nasdaq Capital Market, satisfies applicable market-value and other initial listing standards, and provides written notice of its intention to cure the deficiency, potentially through a reverse stock split.
- If Aprea is not eligible for an additional period or otherwise fails to regain compliance, Nasdaq may issue a delisting determination. The company would then have the right to appeal to a Nasdaq Hearings Panel.
- Management stated that it intends to monitor the closing bid price and may consider available options to regain compliance. The filing provides no assurance that compliance or other listing requirements will be maintained.
Key Facts for Investors to Verify
- Whether APRE regained compliance by December 26, 2022 or received an additional compliance period.
- Whether the company effected a reverse stock split or transferred its listing to the Nasdaq Capital Market.
- Any subsequent Nasdaq delisting determination, appeal, or other listing-status update.
- The company’s financial condition and capital resources, which are not addressed in this filing.